Cyndea Pharma bases its activities upon the manufacturing and development of steroid based generic drugs.
Generic steroid based drugs corresponding to the therapeutic class of sex hormones and regulators of the gonadal function:
- Mainly including the progestins, estrogens and androgens group. They are mostly related to the field of women’s health and associated with the following applications.
-
- Reproductive health: : primarily focused on hormonal contraception using oral contraceptives; mini-pills (progestin only) and combined pills (combination of progestin and estrogen).
- Hormone therapies: treatment for menstrual cycle regulation, dysmenorrhea and other menstrual cycle abnormalities.
- Hormone replacement therapy: mainly focused on the palliation of symptoms and signs of menopause.
- Oncology treatments of hormone-dependent tumours such as those found in breast, endometrial, uterine or prostate cancer.
This group makes up the core of the product portfolio developed and manufactured by Cyndea Pharma thus becoming a reference company in generic drugs within the field of Women’s Health and hormone-dependent cancer therapies.
Generic steroid based drugs corresponding to the therapeutic class of adrenal corticosteroids:
- Used in accordance with their anti-inflammatory properties. Depending on their route of administration, they can be used for the treatment of various conditions including asthma and allergic rhinitis. They can also be used for various eye treatments; for skin treatments such as dermatitis, psoriasis or eczema; for various applications in traumatology and rheumatology; or for the treatment of intestinal inflammation.
Together with the already established products in the market, most being in solid oral dosages (tablets in particular), there is a whole range of possibilities regarding the emergence of new products deriving from already existing highly specialised ones: new concentrations, new combinations and new therapeutic applications. These possibilities are often related to the development of new routes of drug administration such as gels, transdermal patches, subcutaneous implants or vaginal rings. Cyndea Pharma includes, as part of its strategic development plan, the development and manufacturing of generic versions of all these new pharmaceutical forms as well as presentations that may arise, which represent an improvement in the efficiency, safety, quality and adherence to these types of treatments.
Sexual hormones
Products
Presentations
Positioning
Drospirenone3mg + EE 0,03mg
21 o 21+7 tablets
Sales leader (Progestagen of 4th Generation). Anti-mineralocorticoid profile (no weight gains). Minimum side effects (spotting, breast tension).
Drospirenone3mg + EE 0,03mg
21 o 21+7 tablets
Sales leader (Progestagen of 4th Generation). Anti-mineralocorticoid profile (no weight gains). Minimum side effects (spotting, breast tension).
Drospirenone3mg + EE 0,03mg
24 + 4 tablets
Sales leader (Progestagen of 4th Generation). Anti-mineralocorticoid profile (no weight gains). Minimum side effects (spotting, breast tension).
Desogestrel 75 µg
28 tablets
Progestan only. Suitable for breast-feeding women. Suitable for women with potential risk factors to use COSs .
Dienogest 2mg + EE 0,03mg
21 o 21+7 tablets
Excelent antiandrogenic profile. Peripheral action in ovaries and endometrium. Possible antiacne indication.
Chlormadinone 2mg + 0,03mg
21 o 21+7 tablets
Good antiandrogenic profile. Low side effects
Desogestrel 0,150mg + EE 0,02mg
21 tablets
Wide range of prescriptions. Good tolerability and low side effects.
Desogestrel 0,150mg + EE 0,02mg
21 tablets
Wide range of prescriptions. Good tolerability and low side effects.
Levonogestrel 0,1mg + EE 0,02mg
21 o 21+7 tablets
Very low dose. Well known safety and efficacy profile
Norgestimate 0,25mg + EE 0,035mg
21 tablets
Good tolerability and low side effects
Hormonal products
Products
Presentations
Therapeutic indications
Prednisone 2,5mg
30 tablets
treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness. No substantial biological effects.
Prednisone 5mg
30 o 60 tablets
treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness. No substantial biological effects.
Prednisone 10mg
30 tablets
treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness. No substantial biological effects.
Prednisone 30mg
30 tablets
treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness. No substantial biological effects.
